Cutia’s CU-40105 Topical Finasteride Spray NDA Accepted by NMPA, a China First
Cutia Therapeutics (HKG: 2487) announced that the National Medical Products Administration (NMPA) has accepted its...
HKG: 2487
Cutia Therapeutics’ CU-40102 Approved in Hong Kong for Androgenetic Alopecia Treatment
China-based dermatology specialist Cutia Therapeutics (HKG: 2487) announced today that its CU-40102 (finasteride topical spray)...
Shanghai Pharma and Cutia Therapeutic Collaborate on Codon Biopharma’s Innovative Drug Distribution
China’s Shanghai Pharmaceuticals Holding Co., Ltd (SPH, HKG: 2607, SHA: 601607) announced the signing of...
Cutia Therapeutics’ Phase III Results for Lidocaine-Tetracaine Cream to be Presented at CSD Meeting
Cutia Therapeutics (HKG: 2487), a dermatology specialist, is set to present the Phase III clinical...
Cutia Therapeutic’s CU-20401 Shows Positive Results in Phase II Subcutaneous Fat Reduction Study
China-based dermatology specialist Cutia Therapeutic (HKG: 2487) has revealed a positive readout from its Phase...
Cutia Therapeutics’ CU-10201 Receives NMPA Approval for Acne Vulgaris Treatment
Cutia Therapeutics (HKG: 2487), a developer of dermatology therapies, has announced that its CU-10201, a...
Cutia Therapeutics’ CU-30101 NDA Accepted for Review by China’s NMPA
Cutia Therapeutics (HKG: 2487), a company specializing in dermatological treatments, has announced that the National...
Cutia Therapeutics Submits New Drug Application for Androgenic Alopecia Treatment in Hong Kong
Cutia Therapeutics (HKG: 2487), a dermatology-focused pharmaceutical company, has announced the submission of a New...
Cutia Therapeutic’s CU-20401 Shows Promising Safety and Efficacy in Phase I Abdominal Fat Reduction Study
Cutia Therapeutic (HKG: 2487), a China-based dermatology specialist, has announced the successful completion of a...
Cutia Therapeutics Achieves Primary Endpoint in Phase I Study of CU-40101 for Androgenic Alopecia
Cutia Therapeutics (HKG: 2487), a company specializing in dermatological therapies, has announced that its Phase...
Cutia Therapeutics’ CU-20401 Completes Phase I Study for Obesity Treatment
China-based dermatology specialist Cutia Therapeutics (HKG: 2487) has announced the last subject out (LSO) in...
Cutia Therapeutics Files for Market Approval of CU-10201 with NMPA for Acne Treatment
Cutia Therapeutics (HKG: 2487), a developer focused on dermatology therapies, has announced the submission of...
Cutia Therapeutics’ CU-10201 Enters Priority Review for Acne Treatment in China
Dermatology therapy developer Cutia Therapeutics (HKG: 2487) has announced that its CU-10201, a 4% minocycline...
Cutia Therapeutics’ CU-40101 Completes Phase I Clinical Trial for Androgenetic Alopecia
Cutia Therapeutics (HKG: 2487), a developer of dermatology therapies, has announced the completion of the...
Cutia Therapeutics Lists on HKEX with HKD527 Million IPO for Dermatology Therapies
Dermatology therapy developer Cutia Therapeutics (HKG: 2487) has successfully made its initial public offering (IPO),...